Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Brugger

Showing results (71-80 of 120) with videos related to

Pageof 12
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 1999
Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up reportS Fetscher, W Brugger, R Engelhardt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 1999
Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 107 patients with non-small-cell lung cancer: a mature follow-up reportS Fetscher, W Brugger, R Engelhardt, et al.
Journal of Cancer Research and Clinical Oncology|April 25, 2018
Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC)M Faehling, J Achenbach, P Staib, et al.
Seminars in Oncology|April 16, 1998
Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancerW Brugger, S Fetscher, J Hasse, et al.
Journal of Leukocyte Biology|June 1, 1990
Surface phenotype analysis of human monocyte to macrophage maturationR Andreesen, W Brugger, C Scheibenbogen, et al.
Research in Virology|March 1, 1990
Infection of monocytes/macrophages by HIV in vitroH von Briesen, R Andreesen, R Esser, et al.
Annals of the New York Academy of Sciences|July 19, 2001
Dendritic cell-based vaccines in patients with hematological malignanciesW Brugger, A Schneider, T Schammann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 26, 2011
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapyB Coudert, T Ciuleanu, K Park, et al.
Cancer|January 10, 2001
Primary central nervous system lymphoma 1991-1997: outcome and late adverse effects after combined modality treatmentU Herrlinger, M Schabet, W Brugger, et al.
Leukemia|November 22, 1997
A new look at the role of p53 in leukemia cell sensitivity to chemotherapyM Trepel, S Scheding, P Groscurth, et al.
Pageof 12

Showing results (71-80 of 120) with videos related to

Sort By:
Pageof 12
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 1999
Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up reportS Fetscher, W Brugger, R Engelhardt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 1999
Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 107 patients with non-small-cell lung cancer: a mature follow-up reportS Fetscher, W Brugger, R Engelhardt, et al.
Journal of Cancer Research and Clinical Oncology|April 25, 2018
Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC)M Faehling, J Achenbach, P Staib, et al.
Seminars in Oncology|April 16, 1998
Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancerW Brugger, S Fetscher, J Hasse, et al.
Journal of Leukocyte Biology|June 1, 1990
Surface phenotype analysis of human monocyte to macrophage maturationR Andreesen, W Brugger, C Scheibenbogen, et al.
Research in Virology|March 1, 1990
Infection of monocytes/macrophages by HIV in vitroH von Briesen, R Andreesen, R Esser, et al.
Annals of the New York Academy of Sciences|July 19, 2001
Dendritic cell-based vaccines in patients with hematological malignanciesW Brugger, A Schneider, T Schammann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 26, 2011
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapyB Coudert, T Ciuleanu, K Park, et al.
Cancer|January 10, 2001
Primary central nervous system lymphoma 1991-1997: outcome and late adverse effects after combined modality treatmentU Herrlinger, M Schabet, W Brugger, et al.
Leukemia|November 22, 1997
A new look at the role of p53 in leukemia cell sensitivity to chemotherapyM Trepel, S Scheding, P Groscurth, et al.
Pageof 12